tislelizumab
![FDA Delay Coherus' Approvals for PD-1 Inhibitor and Neulasta Biosimilar Injector](https://pharmtales.com/wp-content/uploads/2023/09/FDA-Delay-Coherus-Approvals-for-PD-1-Inhibitor-and-Neulasta-Biosimilar-Injector.jpg)
FDA Delay Coherus’ Approvals for PD-1 Inhibitor and Neulasta Biosimilar Injector
Anika Sharma
Coherus BioSciences has experienced a challenging journey in seeking FDA approval for its PD-1 inhibitor, toripalimab, developed in partnership with ...
![novartis, beigene, tislelizumab, pd-1, eu approval, esophageal cancer, tigit](https://pharmtales.com/wp-content/uploads/2023/09/Novartis-gives-up-on-tislelizumab-BeiGenes-PD-1-inhibitor-approved-in-Europe.jpg)
Novartis gives up on tislelizumab, BeiGeneโs PD-1 inhibitor approved in Europe
Anika Sharma
Novartis has terminated its significant cancer immunotherapy collaboration with BeiGene, ending a partnership that had granted Novartis co-development and co-commercialization ...